These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28808915)

  • 1. Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
    Cámara R; Gozalbo I; Jurado M; Sanz J; Aragón B; Grau S
    Adv Ther; 2017 Sep; 34(9):2104-2119. PubMed ID: 28808915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
    Sung AH; Marcella SW; Xie Y
    J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
    O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
    Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
    Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
    J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
    Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
    Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
    Lazzaro C
    Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
    Dranitsaris G; Khoury H
    Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
    Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
    Rely K; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
    Papadopoulos G; Hunt S; Prasad M
    J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.
    Grau S; de la Cámara R; Sabater FJ; Jarque I; Carreras E; Casado MA; Sanz MA
    BMC Infect Dis; 2012 Apr; 12():83. PubMed ID: 22471553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
    Collins CD; Ellis JJ; Kaul DR
    Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
    Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
    Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.